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Background: PCSK9 is critical for LDL-
cholesterol regulation, but the epigenetic 
regulation of the PCSK9 gene is not clear. 
Results: FoxO3 and Sirt6 suppress the 
PCSK9 gene expression and reduce LDL-
cholesterol. 
Conclusion: Hepatic FoxO3 and Sirt6 
control LDL-cholesterol homeostasis. 
Significance: FoxO3 and Sirt6 are 
important for cardiovascular health. 
ABSTRACT 
Elevated LDL-cholesterol is a risk 
factor for the development of 
cardiovascular disease. Thus, proper 
control of LDL-cholesterol homeostasis is 
critical for organismal health. Genetic 
analysis has identified PCSK9 (proprotein 
convertase subtilisin/kexin type 9) as a 
crucial gene in the regulation of LDL-
cholesterol via control of LDL receptor 
degradation. Although biochemical 
characteristics and clinical implications of 
PCSK9 have been extensively 
investigated, epigenetic regulation of this 
gene is largely unknown. In this work, we 
have discovered that Sirt6, an NAD+-
dependent histone deacetylase, plays a 
critical role in the regulation of the Pcsk9 
gene expression in mice. Hepatic Sirt6 
deficiency leads to elevated Pcsk9 gene 
expression and LDL-cholesterol as well. 
Mechanistically, we have demonstrated 
that Sirt6 can be recruited by forkhead 
transcription factor FoxO3 to the 
proximal promoter region of the Pcsk9 
gene and deacetylates histone H3 at 
lysines 9 and 56, thereby suppressing the 
gene expression. Also remarkably, 
overexpression of Sirt6 in high-fat diet fed 
mice lowers LDL-cholesterol. Overall, our 
data suggest that FoxO3 and Sirt6, two 
longevity genes, can reduce LDL-
cholesterol levels through regulation of 
the Pcsk9 gene. 
____________________________________ 
Elevated LDL-cholesterol is a risk 
factor for cardiovascular disease (1). High 
LDL-cholesterol can be caused by a number 
of dysregulated processes, including 
increased cholesterol biosynthesis, increased 
VLDL secretion, and decreased LDL 
clearance (2). Genetic studies have 
identified mutations in at least three genes 
significantly contribute to autosomal 
dominant hypercholesterolemia (ADH), and 
they are LDL receptor (LDLR), 
apolipoprotein B (APOB), and proprotein 
convertase subtilisin kexin type 9 (PCSK9) 
(3). LDLR plays a major role in the LDL 
clearance. APOB, a protein component of 
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LDL, also interacts with LDLR. PCSK9 can 
modulate the LDL metabolism through 
control of the LDLR degradation in the 
lysosome (3). 
Since the discovery of PCSK9 
mutations in the ADH patients a decade ago 
(4), significant progress has been made in 
the understanding of PCSK9 biochemistry 
and pathophysiology (5). Now we know that 
PCSK9 is expressed mainly in the liver as a 
~72 kDa precursor and can be auto-cleaved 
in the endoplasmic reticulum to a ~62 kDa 
mature form that is secreted to plasma. 
Circulating PCSK9 binds to the extracellular 
EGF-A domain of the LDLR and targets it 
for degradation in the lysosome (5). The 
physiological function of PCSK9 in the 
control of LDL-cholesterol has also been 
confirmed by mouse genetics. 
Overexpression of PCSK9 in mice leads to 
hypercholesterolemia and the Pcsk9 gene 
knockout in mice dramatically reduces 
LDL-cholesterol (6-13). Because of this 
biological function, PCSK9 has become a 
useful target for lowering LDL-cholesterol, 
and several clinical trials are in progress to 
validate the efficacy of targeting PCSK9 for 
cardiovascular disease (14-21). 
PCSK9 gene expression can be 
induced by insulin and pioglitazone, and 
also can be suppressed by glucagon, bile 
acids, berberine, fibrate, and oncostatin M 
(22-32). PCSK9 protein levels decrease in 
the course of fasting and increase after 
feeding (22,27,29,32-34). A number of 
transcription factors or cofactors have been 
shown to regulate the PCSK9 gene 
expression, including sterol-response 
element binding proteins (SREBP-1/2), 
hepatocyte nuclear factor 1A (HNF1A), 
farnesoid X receptor, peroxisome 
proliferator-activated receptor gamma,  liver 
X receptor, and histone nuclear factor P 
(24,28,29,33-37). However, how the PCSK9 
gene expression is controlled by epigenetic 
chromatin remodeling is not clear. In this 
work, we have identified sirtuin 6 (SIRT6) 
as a critical histone deacetylase for the 
PCSK9 gene regulation and LDL-cholesterol 
homeostasis. 
MATERIALS AND METHODS 
Animal Studies — FoxO1 (forkhead 
box O1), FoxO3, FoxO1/3/4, Sirt1, and 
Sirt6 liver-specific knockout mice were 
produced by crossing floxed mice with an 
Albumin-Cre line from the Jackson 
Laboratory. Animals were maintained on the 
following genetic background: FoxOs floxed 
mice on C57BL/6J:129/Sv:FVB, Sirt1floxed 
mice on C57BL/6J:129/Sv,  and Sirt6 floxed 
mice on NIH Black Swiss:129/Sv:FVB. 
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Genotyping was carried out as previously 
described (38-40). High-fat diet (60% 
calories from fat) was purchased from 
Harlan Laboratories (Madison, WI). For the 
VLDL secretion analysis, mice were fasted 
for 4 h before a dose of 500 mg/Kg body 
weight Triton WR1339 was injected via tail 
vein. Blood samples were collected and 
analyzed as previously described (41). All 
animal procedures were performed in 
accordance with the Guide for Care and Use 
of Laboratory Animals of the National 
Institutes of Health and were approved by 
the Institutional Animal Use and Care 
Committee of Indiana University School of 
Medicine. 
Plasmid constructs and adenoviruses 
— For mouse Pcsk9 gene promoter analysis, 
we cloned the short promoter (-128 .. +330 
bp relative to the transcriptional start site) 
together with the 5' untranslated region 
(UTR) into pGL4.10 vector (Promega) using 
the following primers: mPcsk9-pro-Forward, 
5'-GGCCCAGGAGAAGTTAGTTAATA-
3', mPcsk9-pro-Reverse, 5'-
ATGTCTCTGGGGAGCCAA-3'. Human 
FOXO3 and SIRT6 and mouse HNF1A 
coding sequences were cloned into pcDNA3 
(Invitrogen) with FLAG or HA tag. 
Adenoviruses for SIRT6 and FOXO3 
overexpression were generated as previously 
described (39,42). Mouse Pcsk9 shRNAs 
were designed using the BLOCK-iT RNAi 
Designer (Invitrogen) and DNA oligos were 
cloned into a pENTR/U6 vector for further 
adenovirus generation. The sequence of the 
Pcsk9 shRNA used in this work is: 5'-
CAGGACGAGGATGGAGATTAT-3'. For 
Sirt6 gene overexpression in vivo, 
adenoviruses were injected into mice via tail 
vein at a dose of 5 ×108 pfu. 
Serum and liver cholesterol analysis 
— Blood samples were collected from 
overnight fasted mice. Hepatic lipids were 
extracted as previously described (39). Total 
cholesterol and HDL- and LDL/VLDL-
cholesterol were analyzed using assay kits 
from Wako Chemicals USA.  
Luciferase reporter assays — Mouse 
Pcsk9 gene promoter (also including 5' 
UTR) was analyzed in HEK293 cells using 
pGL4.10 luciferase reporter system together 
with an internal control Renilla luciferase 
reporter as previously described (39).  
mRNA analysis — Total RNAs were 
isolated from cells and tissues using TRI 
Reagent (Sigma). Reverse transcription was 
performed using a cDNA synthesis kit 
(Applied Biosystems). Real-time PCR was 
performed using GoTaq qPCR Master Mix 
(Promega). The primers used in PCR 
reactions are as follows: mMttp-Forward, 5'- 
5 
ATGATCCTCTTGGCAGTGCTT -3'; 
mMttp-Reverse, 5'- 
TGAGAGGCCAGTTGTGTGAC -3'; 
mPcsk9-Forward, 5'-
TGGAACCTGGAGCGAATTAT-3'; 
mPcsk9-Reverse, 5'-
CACCCTGGATGCTGGTATCT-3'; 
mSirt6-Forward, 5'-
ACGTCAGAGACACGGTTGTG-3'; 
mSirt6-Reverse, 5'-
CCTCTACAGGCCCGAAGTC-3'. Real-
time PCR data were normalized to an 
internal control Ppia and relative fold 
changes (experimental group/control) were 
also calculated. 
Protein analysis — Cell and tissue 
extract preparation, immunoprecipitation, 
and immunoblotting were performed as 
described previously (39). The following 
antibodies were used: anti-Actinin, anti-HA, 
anti-FoxO1, anti-FoxO3, anti-acetylated 
lysine (Cell Signaling Technology), anti-
LDLR and anti-Pcsk9 (Cayman Chemical), 
anti-HNF1A (Santa Cruz Biotechnology), 
and anti-FLAG and anti-SIRT6 (Sigma).  
Chromatin immunoprecipitation 
(ChIP) — Chromatin association analysis 
was performed in mouse primary 
hepatocytes and mouse livers, followed by 
chromatin preparation, immunoprecipitation 
with FLAG (Sigma), HA (Cell Signaling 
Technology), H3K9Ac, H3K56Ac and 
histone H3 (Millipore) antibodies and 
endogenous protein antibodies described 
above, and real-time PCR analysis, as 
described previously (39). ChIP DNA 
amount for gene promoters of interest was 
normalized to that of a housekeeping gene—
Ppia ChIP or total histone H3 ChIP. Primers 
used in the ChIP PCR reactions are: 
mPcsk9-ChIP-Forward, 5'-
CGAAACCTGATCCTTTAGTACC-3'; 
mPcsk9-ChIP-Reverse, 5'-
ATGTCTCTGGGGAGCCAA-3'; mPpia-
ChIP-Forward, 5'- 
CAGACCCACATTCCTGAGGT-3'; 
mPpia-ChIP-Reverse, 5'- 
AAGTCGGTGCTGTGGAAGAC-3'. 
Statistical analysis — Quantitative 
data were presented as mean ± SEM. 
Significance (p<0.05) was assessed by two-
tailed unpaired Student t-test. 
RESULTS 
LDL-cholesterol is elevated in hepatic 
Sirt6 deficient mice 
Sirt6 has been previously shown to 
regulate hepatic triglyceride metabolism and 
cholesterol biosynthesis (38,43). To examine 
which lipoprotein-associated cholesterol 
might be modulated by Sirt6, we analyzed 
cholesterol in HDL and LDL/VLDL 
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fractions of sera from control floxed 
(LoxpT6) and Sirt6 liver-specific knockout 
mice (LKOT6). Whereas there was no 
significant difference in HDL-cholesterol, 
LDL/VLDL-cholesterol levels were 
increased 45% in the LKOT6 mice relative 
to the control LoxpT6 littermates (Figure 1, 
A and B). VLDL secretion was also 
increased in the LKOT6 mice compared to 
the control mice (Figure 1C). Microsomal 
triglyceride transfer protein (Mttp), an 
important factor for VLDL assembly and 
secretion, was moderately upregulated in the 
LKOT6 livers (Figure 1D).  
Sirt6 regulates LDL-cholesterol by 
suppression of the Pcsk9 gene expression 
Since hepatic deficiency of Sirt6 led 
to elevated LDL-cholesterol but not HDL-
cholesterol, we decided to further investigate 
the underlying mechanisms. As Pcsk9 is 
critically involved in LDLR turnover and 
LDL-cholesterol homeostasis (5), we first 
analyzed Pcsk9 mRNA and protein levels in 
control and LKOT6 livers. The results 
showed that Pcsk9 mRNA was increased by 
~3 fold in the LKOT6 mice as compared to 
the control mice (Figure 2A). Consistent 
with an increase in Pcsk9 mRNAs, its 
protein level was also elevated in the 
LKOT6 liver (Figure 2B). Since Pcsk9 
targets LDLR for degradation, we also 
observed a decrease in LDLR in the LKOT6 
liver (Figure 2B). To verify the role of 
Pcsk9 in LDLR degradation, we performed 
Pcsk9 gene knockdown in mouse primary 
hepatocytes. As expected, knockdown of 
Pcsk9 led to a significant increase in the 
LDLR proteins in both wild-type and 
LKOT6 hepatocytes (Figure 2C). 
To explore the regulatory mechanism 
for the Pcsk9 gene by Sirt6, we first 
analyzed promoter sequences of human and 
mouse Pcsk9 genes. In addition to 
previously identified two cis-
elementssterol response element (SRE) 
and HNF1A binding site, we also found a 
consensus binding site for FoxO 
transcription factors (also called insulin 
response elementIRE) (Figure 2D). 
Interestingly, the IRE is completely 
embedded in the HNF1A site. This raised a 
question whether FoxOs could affect 
HNF1A-activated Pcsk9 gene expression. 
We performed luciferase reporter assays for 
the proximal promoter region of mouse 
Pcsk9 gene, which also includes a part of the 
5' untranslated region (UTR) containing the 
HNF1A binding site. To emphasize here, 
our nucleotide numbering (relative to the 
transcription start site) is different from the 
literature because most previous reports 
have numbered the Pcsk9 promoter 
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constructs relative to the translation start 
site. The reporter assay data showed that 
HNF1A activated the reporter and FoxO3 
suppressed the activation by HNF1A (Figure 
2E). To verify that FoxO3 is associated with 
this region in the chromatin, we also 
performed chromatin immunoprecipitation 
(ChIP) analysis. The data revealed a strong 
association between the 5' UTR of the Pcsk9 
gene and FoxO3 (Figure 2F). Interestingly, 
while insulin reduced the association of 
FoxO3 to the 5' UTR of the Pcsk9 gene, the 
association of HNF1A was increased 
(Figure 2, G and H). 
To further demonstrate that FoxO3 
indeed regulates the Pcsk9 gene expression, 
we analyzed Pcsk9 mRNA and protein in 
the livers that were deficient in FoxO1, 
FoxO3, or FoxO1/3/4 (LKO1, LKO3, and 
LTKO, respectively). The data indicated that 
knockout of FoxO3 led to a significant 
increase in the Pcsk9 gene expression in the 
LKO3 livers although Sirt6 mRNA levels 
were not significantly changed (Figure 3, A- 
C). As a result, hepatic LDLR protein was 
decreased in the liver of LKO3 mice relative 
to control mice (Figure 3C). To confirm the 
correlation between Pcsk9 and LDLR, we 
also performed Pcsk9 gene knockdown in 
control and LKO3 mouse primary 
hepatocytes. As anticipated, LDLR protein 
levels were increased after the Pcsk9 gene 
was knocked down (Figure, 3D). Similar to 
LKOT6 mice, LKO3 and LTKO mice also 
had elevated LDL-cholesterol without any 
significant change in HDL-cholesterol 
(Figure 3, E-H). 
Sirt6 interacts with FoxO3 and modulates 
histone acetylation in the Pcsk9 gene 
Since Sirt6 is an NAD-dependent 
histone deacetylase (44-47), it might be 
recruited to the Pcsk9 gene promoter 
through a transcription factor. We tested this 
hypothesis by performing analysis of 
possible protein-protein interactions 
between Sirt6 and HNF1A, FoxO3, or 
SREBP-2 by co-immunoprecipitation (co-
IP). Our data showed that Sirt6 could 
interact with HNF1A and FoxO3 but not 
SREBP-2 (Figure 4, A-D and G). We also 
observed an interaction between FoxO3 and 
HNF1A in HEK293 cells and mouse 
primary hepatocytes (Figure 4, E and F). To 
examine whether Sirt6 has any effect on 
FoxO3 acetylation, we carried out 
immunoprecipitation and immunoblot 
analyses of FoxO3 acetylation in control and 
LKOT6 liver lysates. The data indicated that 
Sirt6 deficiency did not have any significant 
effect on the acetylation of FoxO3 (Figure 
4H). 
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To assess whether Sirt6 could bring 
about epigenetic changes to the Pcsk9 gene 
promoter, we overexpressed either GFP or 
Sirt6 in mouse primary hepatocytes and 
subsequently performed ChIP analysis of 
Sirt6 association and histone H3 acetylation. 
The results showed that Sirt6 was highly 
enriched at the 5' UTR of the Pcsk9 gene 
and H3K9 and H3K56 acetylation levels 
were dramatically decreased in Sirt6 
overexpressed hepatocytes (Figure 5, A and 
B). Conversely, those histone modifications 
were elevated in the liver of LKOT6 mice 
(Figure 5C). These data suggest that Sirt6 
may be involved in these histone 
modifications because Sirt6 is known to 
deacetylate those sites (44-47). Since Sirt6 
could interact with FoxO3, we also 
performed ChIP analysis of histone 
acetylation in FoxO3 overexpressed or 
knockout hepatocytes. Similar to Sirt6 
overexpression, FoxO3 overexpression also 
remarkably reduced acetylation of H3K9 
and H3K56 (Figure 5D). FoxO3 deficiency 
not only dramatically reduced association of 
Sirt6 with the 5' UTR of the Pcsk9 gene but 
also led to an increase of acetylation of 
H3K9 and H3K56 when endogenous protein 
antibodies were used for the ChIP analyses 
(Figure 5, E and F). 
Sirt6 overexpression lowers LDL-
cholesterol in high-fat diet treated mice 
To examine the potential role of 
Sirt6 in the protection against 
hypercholesterolemia, we first analyzed 
Sirt6 gene expression in the liver of mice 
treated with a high-fat diet (HFD) for 2 
months. The hepatic levels of Sirt6 mRNA 
and protein were decreased in the liver of 
HFD fed mice as compared to chow diet 
group (Figure 6, A and B). To test whether 
overexpression of Sirt6 could improve 
hypercholesterolemia, we injected GFP or 
Sirt6 expressing adenoviruses into the HFD 
treated mice. Two weeks later, we analyzed 
hepatic Pcsk9 and LDLR gene expression 
and serum cholesterol. HFD induced Pcsk9 
mRNA and protein levels and Sirt6 
overexpression significantly suppressed the 
Pcsk9 gene expression (Figure 6, B-D). 
With regard to LDLR, HFD induced 
expression of the Ldlr gene, and Sirt6 
overexpression further increased the LDLR 
protein levels (Figure 6, B-D). Whereas 
HDL-cholesterol levels were not changed, 
total and LDL-cholesterol levels were 
significantly decreased in the Sirt6 
overexpressed mice relative to control mice 
on HFD (Figure 6E). These data reinforce 
the notion that Sirt6 plays a critical role in 
the LDL-cholesterol homeostasis. 
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DISCUSSION 
In this work, we have demonstrated 
that hepatic Sirt6 and FoxO3 have an 
important role in the regulation of LDL-
cholesterol homeostasis. Since Sirt6 is 
decreased in the livers of obese animals and 
humans (38,48), it implicates a potential 
consequence for the development of 
hypercholesterolemia, particularly high 
LDL-cholesterol. Previously, it has been 
reported that systemic overexpression of 
Sirt6 in mice can lower LDL-cholesterol 
under conditions of either chow or high-fat 
diet; however, the underlying mechanism is 
not clear (49). According to our data, we 
speculate that downregulation of the Pcsk9 
gene expression may be responsible for the 
low LDL-cholesterol phenotype in the Sirt6 
transgenic mice. Additionally, Sirt6 also 
significantly represses fatty acid and 
cholesterol biosynthetic genes and activates 
fatty acid oxidation genes (38,43). 
Apparently, Sirt6 has a salutary effect on 
lipid homeostasis. 
Since Sirt6 is an NAD-dependent 
deacetylase and mainly targets to histone 
H3, it may be normally recruited by 
transcription factors for regulation of 
specific genes. With regard to the Pcsk9 
gene, SREBP-1/2 and HNF1A have been 
shown to play significant regulatory roles 
(29,31,33,34,36). Our data suggest that Sirt6 
may be recruited by FoxO3 to the Pcsk9 
gene promoter in order to suppress the gene 
expression. FoxO transcription factors are 
known to have both positive and negative 
effects on gene regulation. The negative 
effects of FoxOs can be mediated by several 
different mechanisms, including 
displacement of regulatory cofactors, 
recruitment of co-repressor or histone 
deacetylase, sequestration of other 
transcription factors, or promotion of 
associated protein degradation (50). In the 
case of Pcsk9 gene regulation, our data 
suggest that FoxO3 may suppress the 
HNF1A transcriptional activity on the Pcsk9 
gene promoter by displacing this 
transcription factor and recruiting the 
histone deacetylase Sirt6 as well. This 
regulation may occur during starvation 
because under that condition Sirt6 and 
FoxO3 are both active. As a result of the 
Sirt6 recruitment, deacetylation of H3K9 
and H3K56 by Sirt6 creates a repressive 
state in the chromatin of the Pcsk9 gene 
promoter to suppress the gene transcription. 
Additionally, reduced levels of SREBPs and 
HNF1A may also contribute to the 
downregulation of the Pcsk9 gene during 
fasting (27,29,33). Upon feeding, the 
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activity of FoxO3 and Sirt6 is decreased and 
the levels of nuclear SREBPs are increased, 
the Pcsk9 gene transcription is thus 
activated. With regard to the involvement of 
FoxOs in the regulation of the Pcsk9 gene, 
some questions remain to be addressed in 
the future. First, why does FoxO3 play a 
major role rather than FoxO1 since FoxO1 is 
also highly abundant in the liver as well? In 
consistence with our data, previous reports 
have also shown that FoxO1 does not play a 
significant role in LDL-cholesterol 
regulation (36,51,52). Second, what is the 
role of FoxO3 in the regulation of the Pcsk9 
gene in obese and diabetic conditions? 
Whereas several reports have shown that 
feeding or insulin can induce the Pcsk9 gene 
expression (23,29,53), another one has 
documented an increase in the Pcsk9 
expression in the liver of insulin receptor 
knockdown mice (36). In insulin-deficient 
type I diabetic rats, hepatic Pcsk9 mRNAs 
are dramatically decreased (53); however, in 
ob/ob obese mice, hepatic Pcsk9 mRNAs 
are also decreased by 2 fold (36). Further 
investigation is needed to clarify what 
causes differential regulation of the Pcsk9 
gene expression under those conditions. 
Recently, we have reported that 
FoxO3 and Sirt6 also suppress the Srebp2 
gene expression in the liver (43). This 
suggests that both factors may have a 
coordinated role in cholesterol homeostasis. 
By regulating the Srebp2 gene  the master 
regulator of cholesterol biosynthesis, FoxO3 
and Sirt6 have an impact on total cholesterol 
levels in the circulation. With fine-tuning on 
the Pcsk9 gene expression, Sirt6 and FoxO3 
enhance the salutary effects by lowering 
LDL-cholesterol levels. 
As Pcsk9 plays an important role in 
LDL-cholesterol homeostasis, proper 
regulation of the Pcsk9 gene expression by 
Sirt6 and FoxO3 may contribute to 
cardiovascular health of organisms. It is 
known that both Sirt6 and FoxO3 are 
associated with longevity in mammals 
(47,54-59). Thus, it should be interesting to 
look into how Sirt6 and FoxO3 may 
influence longevity through regulation of 
LDL-cholesterol.  
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FIGURE LEGENDS 
Figure 1. Hepatic Sirt6 knockout leads to elevated LDL-cholesterol levels. (A, B) Serum 
HDL- and LDL-cholesterol (HDL-C and LDL-C, respectively) measurements in 2-3 months 
control floxed (loxpT6) and Sirt6 liver-specific knockout mice (LKOT6, n=10-12). (C) VLDL-
cholesterol (VLDL-C) secretion analysis in control and LKOT6 mice (n=3-4). (D) Real-time 
PCR analysis of Mttp mRNA in the liver of control and LKOT6 mice (n=6-10). Data are mean ± 
SEM; *P ≤ 0.05 by t-test. 
Figure 2. Regulation of the Pcsk9 gene by FoxO3 and Sirt6. (A) Real-time PCR analysis of 
Pcsk9 mRNA in the control and LKOT6 livers (n=3-5). (B) Immunoblot analysis of Pcsk9 and 
LDLR proteins in the control and LKOT6 livers. (C) Immunoblot analysis of Pcsk9 and LDLR 
proteins in mouse primary hepatocytes infected with control GFP (shGFP) and Pcsk9 (shPcsk9) 
shRNA adenoviruses, respectively. (D) Pcsk9 gene promoter analysis. A potential FoxO-binding 
element also called insulin response element (IRE, inside the box) was identified in the 5' 
untranslated region (UTR) of mouse Pcsk9 gene and human PCSK9 proximal gene promoter. 
Sequence numberings refer to the transcriptional start site. The previously characterized HNF1A 
and SREBP2 binding elements were underlined, respectively. (E) Luciferase reporter analysis of 
the proximal promoter (including part of the 5' UTR) of the mouse Pcsk9 gene was performed in 
HEK293 cells that were transfected with respective promoter constructs with GFP, HNF1A, and 
FoxO3. (F) Analysis of FoxO3 association with the 5′ UTR of the Pcsk9 gene was performed 
using ChIP in mouse primary hepatocytes transduced with GFP or FoxO3 expressing 
adenoviruses. Data are shown as fold enrichment relative to GFP. (G, H) ChIP analysis of 
association of FoxO3 and HNF1A with the 5' UTR of the Pcsk9 gene in mouse primary 
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hepatocytes in the absence or presence of 2 nM insulin using control IgG or corresponding 
protein antibodies. Data are presented as fold enrichment relative to the IgG control. Data are 
mean ± SEM; *P ≤ 0.05 by t-test. 
Figure 3. Pcsk9 gene expression and LDL-cholesterol were elevated in FoxO3 liver-specific 
knockout mice. (A) Real-time PCR analysis of Pcsk9 mRNAs in the livers of control, LKO1 
(FoxO1 liver-specific knockout), LKO3 (FoxO3 liver-specific knockout), and LTKO (FoxO1/3/4 
liver-specific knockout) mice (n=4-8). Control values were normalized to 1. (B) Sirt6 mRNAs 
were analyzed by real-time PCR in the livers of control and LKO3 mice (n=4). (C) Western blot 
analysis of Pcsk9 and LDLR proteins in control and LKO3 mouse livers. (D) Immunoblot 
analysis of Pcsk9 and LDLR in mouse primary hepatocytes transduced with shGFP or shPcsk9 
adenoviruses. (E-H) Serum HDL-C and LDL-C were measured in control floxed, LKO3, and 
LTKO mice (n=6-8). Data are mean ± SEM; *P ≤ 0.05 by t-test. 
Figure 4. Sirt6 interacts with HNF1A and FoxO3. (A) Co-IP analysis of a potential interaction 
between Sirt6 and HNF1A by transfection of corresponding DNA plasmids into HEK293 cells. 
(B) The Sirt6-HNF1A interaction was verified in mouse primary hepatocytes by 
immunoprecipitation using Sirt6 antibodies. A positive control histone H3 was also included. (C) 
Co-IP analysis of a possible interaction between Sirt6 and FoxO3 in HEK293 cells. (D) The 
Sirt6-FoxO3 interaction was validated in mouse primary hepatocytes by immunoprecipitation 
with Sirt6 antibodies. Histone H3 was also analyzed in the IP. (E) Co-IP analysis of a potential 
interaction between FoxO3 and HNF1A in HEK293 cells. (F) Immunoprecipitation analysis of 
the FoxO3-HNF1A interaction in mouse primary hepatocytes using FoxO3 antibodies. (G) Co-IP 
analysis indicates no interaction between Sirt6 and SREBP-2 in HEK293 cells. (H) FoxO3 
acetylation analysis of control and LKOT6 liver lysates by immunoprecipitation using FoxO3 
antibodies and immunoblotting with anti-acetyl lysine antibodies. 
 Figure 5. FoxO3 and Sirt6 modulate histone acetylation in the chromatin of the Pcsk9 
gene. (A, B) Association of Sirt6 with the 5′ UTR chromatin of the Pcsk9 gene and histone H3 
acetylation in the same region were analyzed by ChIP in mouse primary hepatocytes transduced 
with GFP and Sirt6 adenoviruses. Data are shown as fold enrichment relative to the GFP control. 
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(C) The acetylation levels of H3K9 and H3K56 were analyzed by ChIP in the 5′ UTR of the 
Pcsk9 gene in control and LKOT6 livers. Data are presented as fold enrichment relative to the 
LoxpT6 control. (D) The effect of FoxO3 overexpression on histone acetylation in the 5' UTR 
chromatin was analyzed using ChIP in mouse primary hepatocytes transduced with GFP or 
FoxO3 expressing adenoviruses. Data are expressed as fold enrichment relative to the GFP 
control. (E, F) ChIP analysis of Sirt6 association with the 5' UTR of the Pcsk9 gene and histone 
H3 acetylation in control and LKO3 mouse primary hepatocytes using corresponding specific 
antibodies. Data in panel E are presented as fold enrichment relative to the IgG control in the 
Loxp3 group and data in panel F are shown as fold enrichment relative to the Loxp3 control. 
Data are mean ± SEM; *P ≤ 0.05 by t-test. 
Figure 6. Sirt6 overexpression reduces Pcsk9 gene expression and serum LDL-cholesterol. 
(A) Sirt6 mRNA levels in in the liver of wild-type (WT) mice (n=5-8) fed chow or 2-month 
high-fat diet (HFD) were analyzed by real-time PCR. (B) Western blot analysis of liver proteins 
from chow or HFD treated WT mice infected with GFP or Sirt6 adenoviruses. (C) Quantitative 
analysis of Pcsk9 and LDLR proteins in Panel B. The immunoblot data were quantified by the 
Quantity One software (Bio-Rad) and normalized to the loading control actinin. (D) Pcsk9 and 
Ldlr mRNAs in the liver of chow or HFD fed mice (n=5-8) that were infected with GFP or Sirt6 
adenoviruses were analyzed by real-time PCR. (E) Cholesterol measurements in the chow and 
HFD fed mice overexpressed GFP or Sirt6 (n=5-8). Data are mean ± SEM; *P ≤ 0.05 by t-test. 
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